Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial
2023 · Annals of Oncology · 299 citations
https://doi.org/10.1016/j.annonc.2023.05.005
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
4
Papers
421
Citations
3
h-index
2
i10-index
I. Ray-Coquard is an academic researcher from Centre Léon Bérard. The author has contributed to research in topics: Ovarian cancer diagnosis and treatment & PARP inhibition in cancer therapy & BRCA gene mutations in cancer. The author has an h-index of 3, co-authored 4 publications.
https://doi.org/10.1016/j.annonc.2023.05.005
https://doi.org/10.1016/j.annonc.2023.09.3110
Click to start Chat